NCT06157918已完成1 期
A Single-Center, Randomized, Open-label, Single-dose, 3-Sequence, 3-Period Rossover Design to Evaluate the Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants
Shanghai Runshi Pharmaceutical Technology Co., Ltd1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2023年12月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
This is a three-period crossover phase I study designed to evaluate the relative bioavailability, food effect, safety and tolerability of SYHA1813 oral solution in healthy participants.
详细描述
Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male aged 18 to 60 years old;
- •Weight more than 50.0 kg and body mass index between 19 to 26.0 kg/m^2;
- •Normal or abnormal results without clinical significance on all tests including medical history, vital signs, physical examination, laboratory evaluation (routine blood, blood biochemistry, urine routine, coagulation function, serum virology, and other related tests), 12-lead electrocardiogram, chest X-ray and other tests;
- •Male participants and their partners must agree to use effective non-hormonal contraception from the first administration of the test drug to 6 months after the last administration of the test drug, even if permanent contraception has already been used, and the male participant does not plan to donate sperm;
- •Voluntarily sign the informed consent form, and cooperate in completing the trial according to the protocol.
排除标准
- •Allergic constitution (allergic to 2 or more kinds of drugs, food, or pollen);
- •Participants with a clear history of neurological disease or psychiatric disease, a history of severe cardiovascular, hepatic, renal, endocrine, respiratory, hematologic, digestive, immune, and other various systemic diseases, or a history of malignant neoplastic disease;
- •Participants who are unable to swallow orally administered drugs, or clinically significant abnormalities in gastrointestinal function that could affect drug absorption, distribution, metabolism, and excretion;
- •Participants who have undergone major surgery within 6 months prior to screening or who are scheduled to undergo surgery during the trial;
- •Participants with 1 or more abnormal vital signs at screening;
- •Abnormal and clinically significant electrocardiograms: QTc interval >450ms;
- •Participants who consumed more than 14 units of alcohol per week in the 4 weeks prior to screening or who had a positive breath test for alcohol at screening;
- •Smoking ≥ 5 cigarettes per day on average within 6 months prior to screening;
- •Participants with a history of drug or substance abuse, or a positive urine drug screen;
- •Participants who have lost blood or donated more than 400 ml of blood within 4 weeks prior to screening or plan to donate blood during the study or within 1 month of the end of the study;
- •Participants who have participated in other clinical trials within 3 months prior to screening;
- •Habitual intake of excessive xanthine or caffeine-containing foods, beverages, or other foods that interfere with drug absorption, distribution, metabolism, excretion within 4 weeks prior to screening;
- •Participants who have taken a special diet (dragon fruit, mango, grapefruit, lime, poppy seed, or food or drink prepared from them) within 7 days prior to screening, or participants who are unable to stop taking the above special diets during the trial;
- •Participants who have used potent inhibitors or inducers of CYP enzymes (e.g., CYP2C9, 2C19, and 3A4) within 4 weeks prior to screening;
- •Participants who have used prescription, over-the-counter, herbal, vitamin, or mineral medications within 2 weeks prior to screening, and participants who have taken medications prior to screening that have not completed 5 half-lives, whichever is longer among the various medications;
- •Participants who cannot tolerate venipuncture or with a history of fainting needle or blood;
- •Participants who are lactose intolerant;
- •Any condition that the investigator considers inappropriate for participation in the study.
结局指标
主要结局
Cmax
时间窗: Up to 120 hours post-dose for eachperiod
Maximum observed plasma concentration
AUC0-∞
时间窗: Up to 120 hours post-dose for eachperiod
Area under the plasma concentration time curve from time zero extrapolated to infinite time
AUC0-t
时间窗: Up to 120 hours post-dose for eachperiod
Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration
次要结局
- V/F(Up to 120 hours post-dose for eachperiod)
- Title:Cl/F(Up to 120 hours post-dose for eachperiod)
- T1/2(Up to 120 hours post-dose for eachperiod)
- Number of participants with Adverse Events(Up to 34 days)
- Tmax(Up to 120 hours post-dose for eachperiod)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet FormulationsRelative BioavailabilityNCT04686669Forendo Pharma Ltd12
已完成
1 期
Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy VolunteersHealthyNCT03021642Merck KGaA, Darmstadt, Germany24
已完成
不适用
Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 ProductsCoenzyme Q DeficiencyNCT05272228University of Primorska25
已完成
1 期
A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy SubjectsHealthy SubjectsNCT01260155Eisai Inc.16
已完成
1 期
A Relative Bioavailability Study of Two Formulations of BCX7353Hereditary AngioedemaNCT03202784BioCryst Pharmaceuticals24